Vaccine and biotechnology company Abera Bioscience reports, as planned, no revenue for the second quarter. The operating loss increased.Operating result was -5.6 million kronor (-0.8). Net result after tax was -5.6 million kronor (-0.8), and per share -0.27 kronor (-0.05). Cash flow from operating activities amounted to -8.3 million kronor (2.6). Cash and cash equivalents amounted to 17.7 million kronor (7.9)."The second quarter of 2026 marks a decisive milestone for Abera. After several years of development work, during the quarter we were able to complete the GMP production of our vaccine candidate Ab-01.12, and we now have an approved and released batch of clinical trial material," comments CEO Maria Alriksson.At the same time, the pace remains high in the company's lab."While advancing our leading projects, we are working intensively to broaden our pipeline with new vaccine candidates and strengthen the data and methods for prioritized candidates. We continue to combine a high pace of development with good cost control and a small, experienced team with broad expertise that can drive several projects in parallel," says Alriksson.Abera Bioscience, million kronorQ2-2026Q2-2025ChangeNet sales00Operating result-5.6-0.8Net result-5.6-0.8Earnings per share, kronor-0.27-0.05Cash flow from operating activities-8.32.6Cash and cash equivalents17.77.9124.1%